Quantum Biopharma (QNTM) Share-based Compensation (2019 - 2026)
Quantum Biopharma recorded quarterly Share-based Compensation of $892057.0 in Q1 2026, up 10.34% quarter-over-quarter from $808452.0 in Q4 2025, and up 206.26% year-over-year from $291272.0 in Q1 2025.
Quantum Biopharma's Share-based Compensation history runs 8 years deep, the most recent figure standing at $892057.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 206.26% year-over-year to $892057.0; the TTM figure through Mar 2026 stood at $3.5 million (up 574.25% YoY), while the FY2025 annual figure was $2.9 million, up 1835.11% from the prior year.
- Share-based Compensation came in at $892057.0 for Q1 2026 at Quantum Biopharma, up from $808452.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q1 2023 to a low of $57743.0 in Q1 2024.
- A 5-year average of $628821.0 and a median of $208717.5 in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 3755.82% in 2023 and tumbled 98.2% in 2024, its largest moves.
- Quantum Biopharma's Share-based Compensation stood at $83161.0 in 2022, then jumped by 51.71% to $126163.0 in 2023, then slumped by 54.23% to $57743.0 in 2024, then soared by 1300.09% to $808452.0 in 2025, then advanced by 10.34% to $892057.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $892057.0, $808452.0, and $996194.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 87.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 892,057.00 |
| Mar 31, 2026 | 892,057.00 |
| Dec 31, 2025 | 808,452.00 |
| Dec 31, 2025 | 808,452.00 |
| Sep 30, 2025 | 996,194.00 |
| Sep 30, 2025 | 996,194.00 |
| Jun 30, 2025 | 849,584.00 |
| Jun 30, 2025 | 849,584.00 |
| Mar 31, 2025 | 291,272.00 |
| Mar 31, 2025 | 291,272.00 |
| Dec 31, 2024 | 57,743.00 |
| Dec 31, 2024 | 57,743.00 |
| Sep 30, 2024 | 65,424.00 |
| Sep 30, 2024 | 65,424.00 |
| Jun 30, 2024 | 111,524.00 |
| Jun 30, 2024 | 111,524.00 |
| Mar 31, 2024 | 57,743.00 |
| Mar 31, 2024 | 57,743.00 |
| Sep 30, 2023 | 126,163.00 |
| Sep 30, 2023 | 126,163.00 |
| Mar 31, 2023 | 3.21 Mn |
| Mar 31, 2023 | 3.21 Mn |
| Mar 31, 2022 | 83,161.00 |
| Mar 31, 2022 | 83,161.00 |
| Jun 30, 2021 | 3.02 Mn |
| Jun 30, 2021 | 3.02 Mn |
| Sep 30, 2020 | 5.16 Mn |
| Sep 30, 2020 | 5.16 Mn |
| Jun 30, 2020 | 262,575.93 |
| Jun 30, 2020 | 262,575.93 |
| Mar 31, 2020 | 1.72 Mn |
| Mar 31, 2020 | 1.72 Mn |
| Dec 31, 2019 | 2.91 Mn |
| Dec 31, 2019 | 2.91 Mn |
| Mar 31, 2019 | 227,730.84 |
| Mar 31, 2019 | 227,730.84 |